Hutchison China MediTech Limited (NASDAQ:HCM) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Separately, Canaccord Genuity set a $30.00 price objective on shares of Hutchison China MediTech Limited and gave the company a “buy” rating in a research report on Monday, July 31st.

Shares of Hutchison China MediTech Limited (HCM) opened at 29.59 on Thursday. The stock has a 50 day moving average of $26.83 and a 200-day moving average of $26.83. Hutchison China MediTech Limited has a 52 week low of $10.61 and a 52 week high of $32.03.

COPYRIGHT VIOLATION WARNING: “BidaskClub Upgrades Hutchison China MediTech Limited (HCM) to Strong-Buy” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/bidaskclub-upgrades-hutchison-china-meditech-limited-hcm-to-strong-buy/1615147.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Hutchison China MediTech Limited by 7.4% during the 1st quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock worth $10,190,000 after buying an additional 35,053 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Hutchison China MediTech Limited during the 2nd quarter worth approximately $5,102,000. Baillie Gifford & Co. raised its position in Hutchison China MediTech Limited by 6.1% during the 2nd quarter. Baillie Gifford & Co. now owns 167,547 shares of the company’s stock worth $3,905,000 after buying an additional 9,655 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Hutchison China MediTech Limited by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock worth $2,420,000 after buying an additional 7,400 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Hutchison China MediTech Limited during the 1st quarter worth approximately $618,000. 4.06% of the stock is owned by institutional investors.

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.